Benjamin F. Edwards & Company Inc. Boosts Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Benjamin F. Edwards & Company Inc. lifted its holdings in Genmab A/S (NASDAQ:GMAB) by 7.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 7,227 shares of the company’s stock after purchasing an additional 478 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Genmab A/S were worth $182,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Capital International Investors lifted its holdings in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares during the period. Harding Loevner LP raised its position in shares of Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after acquiring an additional 85,665 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Genmab A/S by 16.0% during the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Finally, DDD Partners LLC bought a new stake in Genmab A/S during the second quarter valued at about $8,860,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GMAB has been the subject of several analyst reports. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. BTIG Research raised their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Friday, September 20th. Truist Financial decreased their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB stock opened at $24.12 on Friday. The business has a fifty day moving average of $27.10 and a 200 day moving average of $27.87. Genmab A/S has a 1 year low of $23.80 and a 1 year high of $36.12. The firm has a market capitalization of $15.96 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 0.73 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, equities research analysts expect that Genmab A/S will post 1.27 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.